Journal profile · HEMATOLOGY
Iraqi Journal of Hematology
ISSN 2072-8069 · eISSN 2543-2702 · Wolters Kluwer Medknow Publications · India
Iraqi Journal of Hematology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.2 (journal website); JCR Q4 (journal website); diamond open access (no APC); no APC; median 60 days to acceptance (87 articles, last 24 months); 44 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Iraqi Journal of Hematology is published by Wolters Kluwer Medknow Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hemoglobinopathies and Related Disorders, Chronic Myeloid Leukemia Treatments and Chronic Lymphocytic Leukemia Research, together about 27.9% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
This study investigated the expression levels of fragile histidine triad (FHIT) gene among patients with CML and evaluated its association with the response of patients to imatinib mesylate treatment.
From the journal's Aims & Scope
Research area (LetPub): HEMATOLOGY
Editor-in-chief Alaa Fadhil AlwanPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemoglobinopathies and Related DisordersMedicine11.8%
- Chronic Myeloid Leukemia TreatmentsMedicine8.3%
- Chronic Lymphocytic Leukemia ResearchMedicine7.8%
- Acute Myeloid Leukemia ResearchMedicine7.4%
- Iron Metabolism and DisordersMedicine7.3%
- Blood groups and transfusionMedicine6.7%
- Acute Lymphoblastic Leukemia researchMedicine5.4%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q4 · HEMATOLOGY · rank 99/103
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 0.2Publisher website ·
- CiteScore 2026-06
- 0.5LetPub ·
- SJR 2026-06
- 0.13LetPub ·
- SNIP 2026-06
- 0.23LetPub ·
- h-index
- 10OpenAlex ·
- i10-index
- 13OpenAlex ·
- 2-year mean citedness
- 0.46OpenAlex ·
- Self-citation rate
- 50%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 46LetPub ·
Articles by year OpenAlex count · 421 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 46 | 46 | 2 |
| 2025 | 44 | 44 | 20 |
| 2024 | 57 | 57 | 46 |
| 2023 | 39 | 39 | 40 |
| 2022 | 37 | 37 | 50 |
| 2021 | 32 | 32 | 51 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
60 daysMedian, submission to acceptance · P25–P75 40 days – 94 days
- Acceptance to online
- median 65 days (87 articles)
- Submission to online
- median 133 days
- Sample
- 87 articles with submission and acceptance dates (87 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 17 weeksLetPub ·
- Submission to publication (journal-reported)
- about 19 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC-SA | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wolters Kluwer Medknow Publications
- Country or region
- India
- Language
- English
- ISSN
- 2072-8069
- Electronic ISSN
- 2543-2702
- Latest issue on the website
- Volume 15, Issue 1 (June 2026)
- Official links
FAQ
Frequently asked questions about Iraqi Journal of Hematology
What CAS zone is Iraqi Journal of Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Iraqi Journal of Hematology is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Iraqi Journal of Hematology?
The journal's website gives an impact factor of 0.2; this is the journal's own figure, as LetPub lists none for it; CiteScore 0.5, h-index 10.
How long does peer review take at Iraqi Journal of Hematology?
Based on the dates recorded on 87 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 60 days (interquartile range 40–94 days); authors report an average review time of about 17 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Iraqi Journal of Hematology in?
The journal's website gives JCR Q4; by category, HEMATOLOGY Q4 (99/103). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Iraqi Journal of Hematology?
According to LetPub and DOAJ records, Iraqi Journal of Hematology is indexed in ESCI, Scopus and DOAJ.
Is Iraqi Journal of Hematology open access, and what is the APC?
Iraqi Journal of Hematology is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .